We’re Not Just Capturing Moments—We’re Interpreting Them For Action.

AI Vision: From Concept to Reality

With thousands of bedside cameras deployed across 350+ hospitals, we have a unique vantage point allowing for swift development and efficient future deployment of our AI models. This reach ensures AIVision can evolve through real-world scenarios, delivering value at scale.

We’re currently testing motion analysis algorithms integrated within our existing camera infrastructure, laying the foundation for a suite of screening and decision-support applications.  Key to our AI strategy was the acquisition of the Early Detection Neuromotor Assessment (EDNA) platform, which enables the training of video models to assist in identifying neuromotor risk factors, supporting earlier interventions.

While many of these technologies are still under research and development and may require FDA clearance before clinical deployment, they represent AngelEye’s broader vision and investment in a connected, intelligent NICU environment of the future, providing a richer understanding of pediatric health patterns over time.

“Leveraging AngelEye’s installed base and strong hospital partnerships will allow us to rapidly deploy our critically important neonatal EEG monitor into the market, complete with integrated video capabilities. Together, we are enabling a new standard of neurodiagnostics in the NICU.”
Mark O’Sullivan, CEO of NeuroBell
“At Nationwide Children’s Hospital, our mission is to fuel scientific discovery for better patient care and advance the field of pediatrics through collaboration and innovation. AngelEye’s acquisition of the EDNA technology aligns with this mission, holding immense potential for making early detection assessments more widely accessible, ultimately improving care for children everywhere. We’re thrilled to expand our strategic research collaboration with AngelEye Health on the EDNA portfolio within our Research Institute.”
– Matt McFarland, Nationwide Children’s Hospital Innovation Team
“Early detection is critical for improving long-term outcomes for neonates and high-risk infants. Today, without early, validated, and accessible assessments for newborns, families and clinicians wait for clinical symptoms or significant delays to be identified, which can take weeks or months. AngelEye’s acquisition of the EDNA portfolio is a game-changer, providing clinicians with essential tools to identify and stratify high-risk babies earlier.”
– Kathi Randall, NeuroNICU Consultant
 “By combining our industry-leading footprint with EDNA’s portfolio, we gain the ability to extend our reach beyond engagement and into the realm of supporting clinical care. This strategic transaction enables us to use our established relationships and infrastructure in the NICU to provide clinicians a greater capability to identify at-risk patients and support their care journey in the NICU and beyond.”
– Christopher Rand, CEO AngelEye Health

Clinical Collaboration & Strategic Partnerships

AngelEye is currently working with several talented partners to make the vision of the intelligent pediatric unit a reality. We invite researchers, clinicians, and health systems to collaborate on next-generation tools and studies that will validate and expand the clinical utility of AI in pediatric units. These partnerships are key to ensuring ethical, evidence-based deployment of machine learning. If you are interested in accelerating the pediatric unit of the future together, please click the button below to connect with us.

I’m Interested in Partnering!
PROUD PARTNERS

Built on a Strong Foundation

EDNA’s algorithms and clinical service model have been developed in collaboration with leading scientists and hospitals, including Nationwide Children’s Hospital. Ongoing research is underway to validate further and discover additional sensor-based algorithms and services for newborns.

This page contains information about a medical device product that has not yet received clearance from the U.S. Food and Drug Administration (FDA). The product is currently undergoing the necessary regulatory review process, and its safety and efficacy have not yet been established. Any statements regarding the product’s potential benefits are based on preliminary data and are subject to change upon further evaluation and FDA approval.